A preclinical gene‑replacement study reported restoration of SYNGAP1 function that rescued epilepsy and behavioral deficits in models of SYNGAP1‑related disorders, according to a recent publication. The work demonstrated both molecular correction and functional benefit across seizure and neurodevelopmental endpoints, supporting SYNGAP1 as an actionable target for gene therapy programs. Investigators detailed vector design and outcome measures relevant to translational development.